Pulse Biosciences (PLSE) Resumen de Acciones
Pulse Biosciences, Inc. es una novedosa empresa de medicina bioeléctrica. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 0/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
PLSE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Pulse Biosciences, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$53.11 |
| Máximo en las últimas 52 semanas | US$58.90 |
| Mínimo de 52 semanas | US$12.56 |
| Beta | 1.62 |
| Cambio en 1 mes | 19.24% |
| Variación en 3 meses | 111.51% |
| Cambio de 1 año | 237.42% |
| Variación en 3 años | 1,109.80% |
| Variación en 5 años | 157.57% |
| Variación desde la OPV | 1,173.62% |
Noticias y actualizaciones recientes
Actualización de narrativa • Sep 09
PLSE: Pivotal nsPFA Trials And Early Data Will Drive Bullish Outlook
Analysts have revised their fair value estimate for Pulse Biosciences to $58 from $35, citing growing confidence in the company's differentiated nanosecond pulse field ablation platform, positive early clinical signals, and the potential impact of ongoing pivotal studies and future partnerships. Analyst Commentary on Pulse Biosciences Recent Street research on Pulse Biosciences has taken a more constructive tone, with several bullish analysts highlighting the company’s nanosecond pulsed field ablation platform and early clinical data as key supports for their valuation work.
Actualización de narrativa • Aug 26
PLSE: Pivotal Nanosecond Ablation Data And Partnerships Will Shape 3b Market Access
Analysts have lifted the fair value estimate for Pulse Biosciences to $45.25 from $41, citing Street research that highlights its differentiated nanosecond pulsed field ablation platform, positive early clinical data, progress in pivotal studies, and what they view as improving success probabilities following recent updates. Analyst Commentary Recent Street research on Pulse Biosciences centers on the potential of its nanosecond pulsed field ablation platform, the pace of clinical development, and how these factors feed into valuation and execution risk for investors following the story into late 2026.Actualización de narrativa • Aug 12
PLSE: Clinical And Regulatory Progress Will Test Access To 3b Ablation Market
The analyst price target for Pulse Biosciences has been reset from about $30.67 to $41.00, with analysts pointing to improving success probabilities for its nanosecond pulsed field ablation platform and continued clinical and regulatory progress as key drivers of their updated views. Analyst Commentary Recent Street research on Pulse Biosciences highlights both optimism around the nanosecond pulsed field ablation platform and a focus on the execution risks that come with an early stage commercial story.
Nueva narrativa • Aug 07
Slower Pulsed Field Ablation Adoption Will Limit Revenue Scale And Delay Profitability
Catalysts About Pulse Biosciences Pulse Biosciences develops medical devices based on nanosecond pulsed field ablation technology for cardiac and thyroid procedures. What are the underlying business or industry changes driving this perspective?Recent updates
Actualización de narrativa • Sep 09
PLSE: Pivotal nsPFA Trials And Early Data Will Drive Bullish Outlook
Analysts have revised their fair value estimate for Pulse Biosciences to $58 from $35, citing growing confidence in the company's differentiated nanosecond pulse field ablation platform, positive early clinical signals, and the potential impact of ongoing pivotal studies and future partnerships. Analyst Commentary on Pulse Biosciences Recent Street research on Pulse Biosciences has taken a more constructive tone, with several bullish analysts highlighting the company’s nanosecond pulsed field ablation platform and early clinical data as key supports for their valuation work.Actualización de narrativa • Aug 26
PLSE: Pivotal Nanosecond Ablation Data And Partnerships Will Shape 3b Market Access
Analysts have lifted the fair value estimate for Pulse Biosciences to $45.25 from $41, citing Street research that highlights its differentiated nanosecond pulsed field ablation platform, positive early clinical data, progress in pivotal studies, and what they view as improving success probabilities following recent updates. Analyst Commentary Recent Street research on Pulse Biosciences centers on the potential of its nanosecond pulsed field ablation platform, the pace of clinical development, and how these factors feed into valuation and execution risk for investors following the story into late 2026.Actualización de narrativa • Aug 12
PLSE: Clinical And Regulatory Progress Will Test Access To 3b Ablation Market
The analyst price target for Pulse Biosciences has been reset from about $30.67 to $41.00, with analysts pointing to improving success probabilities for its nanosecond pulsed field ablation platform and continued clinical and regulatory progress as key drivers of their updated views. Analyst Commentary Recent Street research on Pulse Biosciences highlights both optimism around the nanosecond pulsed field ablation platform and a focus on the execution risks that come with an early stage commercial story.Nueva narrativa • Aug 07
Slower Pulsed Field Ablation Adoption Will Limit Revenue Scale And Delay Profitability
Catalysts About Pulse Biosciences Pulse Biosciences develops medical devices based on nanosecond pulsed field ablation technology for cardiac and thyroid procedures. What are the underlying business or industry changes driving this perspective?Actualización de narrativa • Jul 29
PLSE: Cardiac Ablation Data And Index Inclusion Will Guide Fairly Valued Outlook
Analysts have lifted their price target on Pulse Biosciences to $35 from $30, citing preliminary support for the nsPFA platform's safety and efficacy profile in cardiac ablation and its potential to address a large electrophysiology market opportunity. Analyst Commentary on Pulse Biosciences Recent Street research on Pulse Biosciences points to growing confidence in the potential of its nanosecond pulsed field ablation, or nsPFA, platform in cardiac ablation.Actualización de narrativa • Jul 10
PLSE: Ablation Platform And Clinical Data Will Drive Access To 3b Market
Analysts have lifted the fair value estimate for Pulse Biosciences from about $22 to roughly $30.67 per share, citing the company’s differentiated nanosecond pulsed field ablation platform and the roughly $3 billion electrophysiologists ablation market opportunity as key drivers behind a Street price target of $32. Analyst Commentary Recent Street research on Pulse Biosciences centers on the potential of its nanosecond pulsed field ablation platform and how that might justify the latest fair value estimate and price targets around US$32 per share.Actualización de narrativa • Jun 26
PLSE: Nanosecond Cardiac Ablation Platform Will Pursue Expanding Electrophysiology Opportunity
Analysts raised their price target on Pulse Biosciences stock from $30 to $32, citing its differentiated nanosecond pulsed field cardiac ablation platform and the $3 billion electrophysiology ablation market, which they estimate is growing 10% to 15% annually, with potential for the company to capture a meaningful share. Analyst Commentary Bullish analysts covering Pulse Biosciences emphasize that the stock is now being valued around a clearly defined opportunity in cardiac ablation, supported by a specific US$32 price target.Nueva narrativa • Feb 09
Early Thyroid And Cardiac Applications Will Establish A Powerful Medical Device Platform
Catalysts About Pulse Biosciences Pulse Biosciences develops and commercializes medical devices that use proprietary nanosecond pulse field ablation technology for soft tissue and cardiac applications. What are the underlying business or industry changes driving this perspective?Artículo de análisis • Dec 21
Pulse Biosciences (NASDAQ:PLSE) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Artículo de análisis • Jun 12
Here's Why We're Not At All Concerned With Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Artículo de análisis • Feb 07
We're Not Very Worried About Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Pulse...Seeking Alpha • May 16
Pulse Biosciences Stock: Signs Of Life Following Q1 Update
Summary We recap Q1 developments from Pulse Biosciences, Inc. The FDA has cleared the company's percutaneous electrode system, while the surgical clamp device for cardiac indications is still in the preclinical trial phase. Pulse Biosciences is making progress in its commercialization strategy, but financial uncertainties may keep the stock under pressure. Read the full article on Seeking AlphaArtículo de análisis • May 10
We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Artículo de análisis • Dec 25
We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Pulse Biosciences...Artículo de análisis • Sep 04
We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Artículo de análisis • Mar 08
Pulse Biosciences (NASDAQ:PLSE) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Rentabilidad de los accionistas
| PLSE | US Medical Equipment | Mercado US | |
|---|---|---|---|
| 7D | -0.2% | -5.5% | -0.9% |
| 1Y | 237.4% | -18.1% | 13.9% |
Rentabilidad vs. Industria: PLSE superó a la industria US Medical Equipment, que obtuvo un rendimiento del -18.1% el año pasado.
Rentabilidad vs. Mercado: PLSE superó al mercado US, que obtuvo un rendimiento del 13.9% el año pasado.
Volatilidad de los precios
| PLSE volatility | |
|---|---|
| PLSE Average Weekly Movement | 9.0% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Precio estable de las acciones: PLSE no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de PLSE (9%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2014 | 116 | Paul LaViolette | www.pulsebiosciences.com |
Pulse Biosciences, Inc. es una novedosa empresa de medicina bioeléctrica. Ofrece el sistema nPulse, una novedosa plataforma de ablación de campo pulsado en nanosegundos para tratar lesiones benignas de la piel; el sistema de electrodos percutáneos nPulse Vybrance para la ablación de tejidos blandos en entornos quirúrgicos; la pinza quirúrgica cardíaca nPulse, diseñada para el tratamiento quirúrgico de la fibrilación auricular (FA); nPulse Cardiac Catheter System, diseñado para realizar una ablación circunferencial o circular en un solo ciclo de tratamiento; y nPulse Console, una plataforma de software basada en consola diseñada para adaptarse al flujo de trabajo clínico preferido por los médicos. La empresa se conocía anteriormente como Electroblate, Inc. y cambió su nombre a Pulse Biosciences, Inc. en diciembre de 2015.
Resumen de fundamentos de Pulse Biosciences, Inc.
| Estadísticas fundamentales de PLSE | |
|---|---|
| Capitalización bursátil | US$3.79b |
| Beneficios(TTM) | -US$80.06m |
| Ingresos (TTM) | US$1.19m |
3,197x
Ratio precio-ventas (PS)-47.3x
Ratio precio-beneficio (PE)¿Está PLSE sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de PLSE | |
|---|---|
| Ingresos | US$1.19m |
| Coste de los ingresos | US$1.18m |
| Beneficio bruto | US$3.00k |
| Otros gastos | US$80.06m |
| Beneficios | -US$80.06m |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.12 |
| Margen bruto | 0.25% |
| Margen de beneficio neto | -6,755.78% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado PLSE a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/14 10:19 |
| Precio de las acciones al final del día | 2026/09/11 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Pulse Biosciences, Inc. está cubierta por 6 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| William Plovanic | Canaccord Genuity |
| Keith Hinton | Freedom Capital Markets |
| Anthony Petrone | Mizuho Securities USA LLC |